Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Canntab Therapeutics Ltd CTABF

Canntab Therapeutics Limited is a Canadian phytopharmaceutical company focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations. The Company’s operations comprise a single segment engaged in the medical marijuana business. The Company’s hard pill cannabinoid formulations provide doctors, patients, and consumers with medical grade solutions. These include once a day and extended-release formulations. Its products include INSTANT RELEASE - (IR Tablet), EXTENDED-RELEASE - (XR Tablet), and ORAL DISSOLVING - O.D. Tablet (ODT). The IR Tablet is a release profile for solid hard tablets. The XR Tablet is a phytocannabinoid vehicle that is designed to directly address the drawbacks and challenges of competing oral delivery systems. ODT is specifically designed to dissolve directly in the patient’s mouth, with an onset of action between five and thirty minutes.


GREY:CTABF - Post by User

Canntab Therapeutics Ltd > Emblem News
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(8)
•••
Comment by Tonydeon Jun 24, 2018 4:49pm
101 Views
Post# 28221143

RE:RE:RE:RE:Emblem News

RE:RE:RE:RE:Emblem News
Canaken1, allow me to start by saying that we do not know exactly what the License Agreement (contact) entails. So let's call this post "speculation" for now! We know that both EMC and Canntab are manufacturers and sellers of the product (mj). Why would Canntab give an open to the world rights (if you allow me to use such a term) when they (Canntab) are able to manufacture and sell for full profit, rather than just royalties? I'm pretty sure that if Canntab somehow (intentionally or unintentionally) gave EMC full open rights, it would have been noted in last October's news release. If it was missed, I think we're in for a rough ride! (So, as an example, if someone ask me to Do something, I have every right do the opposite. I was never told Not to - do the opposite). Mind you, I understand and to a certain extent agree with you, but I'm pretty sure that whoever was involved (lawyers, directors, financial officials etc.) Crossed their "T" and Dotted their "i". Lots of " if " "but" and "why" s in this post. We would like for any Canntab official to clarify. By the way selling the product "In the Territory" as you specified in your post, for me it refers to Canada. Canaken1, I guess this is not the response you were expecting. I cannot find any document or news release that refrain Emblem from selling the XR tablets worldwide!! On the other hand can you imagine what will happen if Emblem goes into Australia or Asia?? Maybe someone else can share their opinion.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities